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ABSTRACT 
Introduction: Tumour cell anaerobic metabolism has been reported to be a prognostic factor 
in colorectal cancer.  The present study investigated the association between 
monocarboxylate transporter (MCT) 1, MCT 2, lactate dehydrogenase (LDH) 1 and LDH 5, 
the tumour microenvironment, and outcome in patients with colorectal cancer. 
Methods: A cohort of 150 patients with stage I-III CRC were utilised to assess tumour cell 
expression of MCT-1, MCT-2, LDH-1 and LDH5 by immunohistochemistry. Expression 
levels were dichotomised and associations with tumour factors, the tumour microenvironment 
and survival analysed. 
Results: Nuclear LDH-5 associates with poor prognosis (HR 1.68 95% CI 0.99-2.84, 
p=0.050) and trends towards increased tumour stroma percentage (TSP, p=0.125).  
Cytoplasmic MCT-2 also trends towards increased TSP (p=0.081).  When combined into a 
single score; nuclear LDH-5+TSP significantly associated with decreased survival 
independent of stage (HR 2.61 95% CI 1.27-5.35, p=0.009), increased tumour budding 
(p=0.002) and decreased stromal T-lymphocytes (p=0.014). Similarly, Cytoplasmic MCT-
2+TSP significantly associated with decreased survival (HR 2.32 95% CI 1.31-4.11, 
p=0.003), decreased necrosis (p=0.039), and increased tumour budding (p=0.004). 
Conclusions: The present study reports that the combination of TSP and nuclear LDH-5 was 
significantly associated with survival, increased tumour budding and decreased stromal T-
lymphocytes. This supports the hypothesis that increased stromal invasion promotes tumour 
progression via modulation of tumour metabolism.  Moreover, MCT and LDH may provide 
promising therapeutic targets for patients with stromal-rich CRC. 
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INTRODUCTION 
Colorectal cancer (CRC) is the second most common cause of cancer death in developed 
countries1. Despite improvements in the diagnosis and treatment of CRC, outcomes remain 
poor with a 5-year survival rate of 60% with approximately half of patients dying of their 
disease despite curative resection2. TNM staging is currently the gold standard method to 
predict prognosis and aid treatment decisions for CRC. However, this staging method is 
suboptimal as seen by the variation in outcomes that exists amongst patients of the same 
stage. It is clear that other characteristics intrinsic to the tumour and patient may similarly 
affect oncological outcomes. Investigation of these characteristics as prognostic markers that 
could aid current staging, may allow for more accurate prediction of prognosis, better 
tailoring of treatment and development of novel therapies for CRC.   
The tumour microenvironment, composed of blood vessels, stroma and immune cells that 
regulate paracrine and autocrine signalling to support tumour cells growth and spread is well 
recognised as an important factor in tumour development and outcomes in many solid 
tumours including CRC3. The mechanism by which tumour stroma facilitate tumour 
progression has not been fully elucidated however key theories include the stroma producing 
factors that can influence local and systemic inflammation, tumour pH, and tumour 
metabolism4.  
Of these, tumour metabolism has been a major focus of current research. Tumour cells favour 
glycolysis as a method of glucose metabolism, even in the presence of normal oxygen partial 
pressures5. Indeed, this phenomenon termed the Warburg effect may be facilitated by the 
tumour-supporting stroma. It has previously been reported that in patients with colorectal 
cancer, increased tumour cell expression of enzyme pathways associated with anaerobic 
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metabolism and lactate extrusion, including lactate dehydrogenase isoenzyme 5 (LDH 5) and 
monocarboxylate transporter 1 (MCT1), was associated with an increase in the ability of 
cancer-associated fibroblasts to uptake and oxidate lactate, suggesting a reciprocal role in 
supporting tumour cell metabolism6.  It is of interest then that a high tumour stroma 
percentage has been reported to be associated with less tumour necrosis7.  As both of these 
characteristics have previously been shown to be associated with increasing T stage, this 
supports the hypothesis that one of the mechanisms by which an expanded stroma facilitates 
disease progression is by the modulation of tumour cell metabolism, allowing continued 
tumour growth. It is clear however that further work is required.  
The aim of the present study was to investigate the association between key pathways 
associated with tumour cell anaerobic metabolism, the tumour microenvironment, 
clinicopathological characteristics and outcome in patients with colorectal cancer. 
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MATERIALS AND METHODS 
Patient Cohort 
Patients were identified from a prospectively collected and maintained database of colorectal 
cancer resections at a single surgical unit within the Glasgow Royal Infirmary. Patients who 
were considered to have undergone potentially curative resection of Stage I–III CRC between 
1997 and 2007 and whose tumour resection was included in a previously constructed CRC 
tissue microarray (TMA) were included. Patients who died within one month of surgery were 
excluded. The West of Scotland Research Ethics Committee approved the study. 
Tumours were routinely staged using the fifth edition of the TNM classification8. Tumour 
differentiation was graded as well/moderate or poor in accordance with Royal College of 
Pathologists guidelines9. Venous invasion was measured using Elastica staining. Additional 
clinical data was taken from pathological reports following resection. Patients with stage III 
and high-risk stage II disease were considered for 5-fluorouracil-based adjuvant 
chemotherapy according to treatment guidelines at the time. Patients were routinely followed 
up for 5 years following surgery. Date and cause of death were crosschecked with the cancer 
registration system and the Registrar General (Scotland). Cancer-specific survival (CSS) was 
measured from date of surgery until the date of death from CRC.  
 
Assessment of the systemic inflammatory response 
Pre-operative C-reactive protein (CRP), serum albumin and differential white cell count 
measured within 30 days before surgery were recorded prospectively.  The modified Glasgow 
Prognostic Score (mGPS) was calculated as previously described10; patients with a normal 
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CRP ( 10 mg l−1) were allocated a score of 0, an elevated CRP (>10 mg l−1) alone a score of 
1 and an elevated CRP and low albumin (<35 g l−1) a score of 2.  
 
Assessment of the tumour microenvironment 
Using routine haematoxylin and eosin-stained sections of the deepest point of invasion, the 
generalised inflammatory cell infiltrate at the invasive margin was assessed using Klintrup–
Mäkinen (KM) grade and the extent of tumour stroma was assessed using tumour stroma 
percentage (TSP), both as previously described11,12. Tumour-infiltrating T-lymphocyte 
density at the invasive margin and within the cancer cell nests was assessed using 
immunohistochemistry as previously described3.  
 
Western Blots 
All antibodies were validated using western blotting (Figure S1). Standard lysates, HeLa 
whole cell lysate and NIH/3T3 whole cell lysate (SantaCruz Bio, CA, USA) and 293T whole 
cell lysate (Abcam, UK) were separated on a 10% (w/v) polyacrylamide gel and transferred 
onto a polyvinylidene fluoride (PVDF) membrane (Millipore, MA, USA). Membranes were 
blocked for 1hr and then incubated overnight at 4°C with primary antibodies for MCT-1 and 
MCT-2 at 1:500 (Santa Cruz Bio, CA, USA) or LDH1 and LDH5 at 1:5000 (Abcam, UK). 
The membranes were then incubated with the secondary antibody, Donkey anti-goat IgG-
HRP (Santa Cruz Bio, CA, USA) for MCT1/2 and Anti-rabbit IgG-HRP (Cell Signaling 
Tech, USA) for LDH1/5. Bound antibodies were visualized by chemiluminescence 
(Thermoscientific, IL, USA).  
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Immunohistochemistry 
Immunohistochemistry was used to examine four markers of cellular metabolism; LDH1, 
LDH5, MCT1 and MCT2, (Figure S2) in a pre-constructed CRC TMA. The TMA consisted 
of 0.6mm2, 5µm thickness cores of CRC tissue in quadruplicate per patient. The TMA was 
dewaxed and rehydrated using histoclear and graded alcohols. Antigen retrieval was 
undertaken by heating under pressure for 5 mins with EDTA buffer (pH9) for MCT-1/2 or 
Citrate buffer (pH6) for LDH1/5. Endogenous peroxidases were quenched with 3% hydrogen 
peroxide for 20 mins and slides blocked with 5% normal horse serum (MCT-2) or 10% 
casein (MCT-1 and LDH1/5) for 30 mins. The slides were then incubated with primary 
antibody for MCT-1 (1:200) and MCT-2 (1:75) overnight at RT or for LDH-1 (1:600) and 
LDH-5 (1:300) for 75 mins at RT. Protein expression was amplified by incubation with 
ImmPress anti-goat IgG reagent (Vector laboratories, USA) for MCT1/2 or Envision (Dako) 
for LDH1/5. Protein expression was visualized using chromagen 3,3’-diaminobenzidine 
(Vector). The TMA was then counterstained with haemotoxylin, dehydrated and mounted in 
distrene, plasticizer, xylene (DPX).  
 
Scoring Method 
The stained TMAs were scanned using a Hamamatsu NanoZoomer (Welwyn Garden City, 
Hertfordshire, UK) at x20 magnification and visualized via Slidepath Digital Image Hub 
(Leica Biosystems, Milton Keynes, UK).  Tumour cell expression was assessed using the 
weighted histoscore by examiners blinded to the clinical data (MCT 1 and 2 JC, LDH 1 and 5 
SM).  15% of tumours were co-scored by the other examiner to ensure accuracy with a 
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minimum interclass correlation coefficient (ICCC) of 0.713. Expression within the tumour cell 
membrane, cytoplasm and nucleus was scored separately. The weighted histoscore is 
calculated by multiplying the percentage density of cells stained by x0 if negative; x1 if 
weak; x2 if moderate; x3 if strong. The score gives a range from 0-300.  
 
Statistical analysis 
Cut off values to split each factor into low and high expression were determined using ROC 
analysis (Table S1). The relationship between clinicopathological characteristics, local and 
systemic inflammatory responses, and markers of tumour cell metabolism was examined 
using the Chi-squared test for linear trend. The relationship between markers of tumour 
metabolism and CSS was examined by Kaplan Meier curve analysis and the log rank test.  
Multivariate cox regression survival analysis was performed using a backward conditional 
model to assess prognostic independence. All analyses were performed using IBM SPSS 
version 22.0 (Chicago, IL, USA). Significance was set at p<0.05 and all data conforms to the 
REMARK criteria.  
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RESULTS 
A total of 150 patients, who underwent potentially curative resection of stage I-III colorectal 
cancer and had a valid score for all markers, were included (Table S2).  The majority of 
patients were male (55%) and were older than 65 at the time of surgery (61%). Pathological 
assessment confirmed stage I disease in 14 patients (9%), stage II disease in 72 patients 
(48%) and stage III disease in 64 patients (43%). 53 patients (35%) had right-sided colon 
cancer, 46 patients (31%) had left-sided colon cancer and 51 patients (34%) had rectal cancer. 
39 patients (26%) received adjuvant therapy and mismatch repair deficiency was identified in 
22 patients (15%). The median follow up of survivors was 11.0 years (range 6.2-16.1 years) 
with 62 cancer associated deaths and 27 non-cancer deaths. 
Associations between metabolic markers and CSS are shown in Table 1. There was no 
significant association between CSS and MCT-1, MCT-2 and LDH-1 at any cellular location. 
However, nuclear LDH-5 significantly associated with decreased CSS (HR 1.68 95% CI 
0.99-2.84, p=0.050, Figure 1A) and cytoplasmic LDH-5 showed a similar trend towards 
decreased CSS (HR 1.76 95% CI 0.973.20, p=0.058, Figure 1B). As it is hypothesised that 
metabolism may be a reason for increased stromal infiltrate, the relationship between the 
metabolic markers and tumour-stroma percentage (TSP) was investigated (Table S3). No 
significant associations were seen between any metabolic marker and TSP, however 
cytoplasmic MCT-2 trended towards associating with higher TSP (p=0.081) and membrane 
MCT-2 with lower TSP (p=0.112). Similarly, cytoplasmic LDH-5 (p=0.115) and nuclear 
LDH-5 (p=0.145) trended towards an association with lower TSP. Therefore, MCT-2 and 
TSP or LDH-5 and TSP were combined into a single prognostic score graded either as both 
low/one high or as both high. Both cytoplasmic MCT-2+TSP (HR 2.32 95% CI 1.31-4.11, 
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p=0.003, Figure 1C) and nuclear LDH-5+TSP (HR 3.70 95% CI 1.96-6.98, p<0.001, Figure 
1D) significantly associated with poor CSS. 
The relationship between nuclear LDH-5, cytoplasmic MCT-2+TSP, nuclear LDH-5+TSP 
and clinicopathological factors was investigated as shown in Table 2. Nuclear LDH-5 alone 
did not associate with any clinicopathological factors. However, cytoplasmic MCT-2+TSP 
showed significant associations with increased adjuvant therapy (p=0.040), decreased 
necrosis (p=0.039) and increased tumour budding (p=0.004). Trends were also noted towards 
increased stage (p=0.119) and decreased proliferation rate (p=0.134). Similarly, nuclear 
LDH-5+TSP showed significant associations with increased tumour budding (p=0.002) and 
trends towards decreased necrosis (p=0.063) and increased peritoneal involvement (p=0.083). 
The relationship between nuclear LDH-5, cytoplasmic MCT-2+TSP, nuclear LDH-5+TSP 
and inflammatory response was then investigated as shown in Table 3.   Nuclear LDH-5 
alone showed significant associations with decreased regulatory T-cells at the invasive 
margin (p=0.039), within the stoma (p=0.004) and cancer cell nests (p=0.012). Conversely, 
cytoplasmic MCT-2+TSP did not associate with any markers of either the local or systemic 
inflammatory response.  However, nuclear LDH-5+TSP showed a strong association with 
decreased stromal CD3+ T-cells (p=0.014) and trended towards associations with decreased 
regulatory T-cells at the invasive margin (p=0.107) and within the stroma (p=0.101) as well 
as decreased serum lymphocyte levels (p=0.080). 
Next, nuclear LDH-5, cytoplasmic LDH-5, cytoplasmic MCT-2+TSP and nuclear LDH-
5+TSP were entered into multivariate cox regression analysis along with common prognostic 
factors.  Tumour budding (p<0.001), mGPS (p<0.001) and nuclear LDH-5+TSP (p=0.009) 
were independent prognostic factors for CSS in patients with stage I-III CRC 
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The only other thing I was thinking was how did necrosis fit in as the low oxygen as you 
discuss in the intro associates with necrosis which then also inversely associates with TSP.  
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DISCUSSION 
The present study reports a significant association between tumour cell anaerobic 
metabolism, the tumour microenvironment, and survival following surgery for stage I-III 
CRC.  In particular, the combination of TSP and tumour cell expression of cytoplasmic 
MCT-2 or nuclear LDH-5 was prognostic, with nuclear LDH-5+TSP being independent of 
stage.  Furthermore, the combination of TSP and nuclear LDH-5 was significantly associated 
with tumour budding and CD3+ lymphocyte stromal density. Therefore, the results support 
the hypothesis that one mechanism by which increased stromal invasion promotes tumour 
progression is via modulation of tumour metabolism resulting in promotion of tumour 
budding and dampening of the local lymphocytic infiltrate. 
The results of the present study are in keeping with the results of work reporting poorer 
prognosis in CRC patients with over expression of LDH14. Conversely, in the present study 
no association between MCT and prognosis was observed as has been reported in previous 
studies15,16. However, when cytoplasmic MCT-2 was combined with TSP it significantly 
associated with poorer prognosis, as did nuclear LDH-5+TSP. This suggests that metabolism 
is more active in stromal rich tumours. Previous work has reported that expression of 
cytoplasmic MCT-2 and nuclear LDH-5 was prognostic in CRC17,18.  However, this is the 
first to directly assess the relationship between these metabolic markers and stromal invasion.  
The presence of an expanded tumour stroma, of which the predominant cell type is 
fibroblasts, has widely been associated with poorer prognosis in CRC7.  It has been suggested 
that a reciprocal relationship exists between tumour cells and stromal cells which facilitates 
survival and disease progression.  Indeed, the metabolic markers in the present study may act 
to increase the ability of the tumour cell to carry out aerobic glycolysis, LDH by catalysing 
the conversion of pyruvate to lactate and back again, and MCT by lactate extrusion to protect 
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the tumour cell from its acidity14.  It is thought that the lactate extruded into the stromal 
environment is then used as an energy source by the fibroblasts following its oxidation to 
pyruvate, which itself then returns to the tumour cell to be used as a glycolytic substrate19.  
Therefore, as the stroma expands, more pyruvate will be available for the tumour cells to 
utilise allowing them to thrive, suggesting that MCT-2 and LDH-5 may be potential 
therapeutic targets in CRC patients with high stromal infiltration. Preclinical studies of MCT 
inhibitors have shown that they induce apoptosis in CRC cell lines, potentiate the cytotoxicity 
of 5-fU chemotherapy, and slow tumour growth in murine xenograft models20-22.  
The presence of a strong lymphocytic inflammatory cell infiltrate is associated with improved 
survival in colorectal cancer3.  Recently, TSP has been reported to further stratify survival in 
those patients with a weak inflammatory cell infiltrate measured by Klintrup-Makinen grade, 
leading to the creation of the Glasgow Microenvironment Score (GMS)10,23.  In the present 
study, the combination of TSP and nuclear LDH-5 was associated with decreased CD3+ 
lymphocyte stromal density and trended towards associations with decreased regulatory T-
lymphocytes. Furthermore, when nuclear LDH-5 was assessed alone it significantly 
associated with decrease regulatory T-lymphocytes within both the tumour and 
microenvironment. It may be that the highly metabolically active tumour cells remove 
metabolites needed by the regulatory T-cells from the microenvironment, causing them to 
move away from the tumour.  
It was also of interest that the combination of TSP and nuclear LDH-5 or cytoplasmic MCT-2 
was significantly associated with tumour budding.  Tumour budding is associated with poor 
prognosis in colorectal cancer and is thought to be the histological representation endothelial-
mesenchymal transition (EMT)24,25.  It may be that highly metabolically active tumour cells 
in a rich stromal environment cause greater tumour budding and that this underpins the poor 
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prognosis imparted by an expanded tumour stroma and the expression of proteins associated 
with tumour cell metabolism. 
The limitations of the present study include the size of the cohort, which leads to the 
possibility of type 2 error especially in the association between the combination of TSP and 
metabolic markers when assessing associations with characteristics of the tumour 
microenvironment. Furthermore, there were a relatively small number of CSS events, which 
may in part explain why MCT alone was not significantly associated with CSS in this study.   
In conclusion, the present study reports that the combination of TSP and tumour cell 
expression of cytoplasmic MCT-2 or nuclear LDH-5 is associated with poor prognosis.  
Furthermore, the combination of TSP and nuclear LDH-5 was significantly associated with 
increased tumour budding and decreased stromal T-lymphocytes. Therefore, the results 
support the hypothesis that one mechanism by which increased stromal invasion promotes 
tumour progression is via modulation of tumour metabolism resulting in promotion of tumour 
budding and dampening of the local lymphocytic infiltrate.  Moreover, MCT and LDH may 
provide promising therapeutic targets for patients with stromal-rich CRC. 
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Table 1. Metabolic markers and cancer-specific survival in patients undergoing 
potentially curative resection of colorectal cancer (n=150) 
  
 
Nuclear Cytoplasmic Membrane  
N (%) 10yr CSS P N (%) 10yr CSS P N (%) 10yr CSS P 
MCT-1 
Low expression 
High expression 
 
54 
97 
 
65 (7) 
54 (5) 
0.281  
75 
75 
 
62 (6) 
54 (6) 
0.527  
38 
112 
 
69 (8) 
55 (5) 
0.191 
MCT-2 
Low expression 
High expression 
  
107 
43 
 
60 (5) 
52 (8) 
0.277  
38 
112 
 
67 (8) 
55 (5) 
0.327  
146 
4 
 
59 (4) 
25 (22) 
0.344 
LDH-1 
Low expression 
High expression 
 
52 
98 
 
60 (7) 
57 (5) 
0.596  
28 
122 
 
61 (10) 
57 (5) 
0.605  
-  -  - 
LDH-5 
Low expression 
High expression 
 
67 
83 
 
69 (6) 
52 (6) 
0.050  
51 
99 
 
72 (6) 
52 (5) 
0.058  
-  -  - 
MCT-2+TSP 
Both low or one high 
Both high 
 
124 
11 
 
62 (5) 
55 (15) 
0.684  
105 
30 
 
68 (5) 
39 (9) 
0.003  
-  -  - 
LDH-5+TSP 
Both low or one high 
Both high 
 
119 
16 
 
68 (4) 
19 (10) 
<0.001  
116 
19 
 
65 (5) 
40 (12) 
0.069  
-  -  - 
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Table 2: Association of metabolic markers and stromal infiltrate in patients undergoing 
potentially curative resection of colorectal cancer (n=150) 
 
 
Tumour stroma % 
 
Low 
(n=99) High (n=36) P 
Membrane MCT-1 
Low 
High 
 
24 (75) 
75 (73) 
 
8 (25) 
28 (27) 
0.806 
Cytoplasmic MCT-1 
Low 
High 
 
49 (74) 
50 (73) 
 
17 (26) 
19 (27) 
0.815 
Nuclear MCT-1 
Low 
High 
 
38 (73) 
61 (100) 
 
12 (27) 
24 (0) 
0.589 
Membrane MCT-2 
Low 
High 
 
95 (76) 
4 (72) 
 
36 (100) 
0 (0) 
0.112 
Cytoplasmic MCT-2 
Low 
High 
 
31 (84) 
68 (69) 
 
6 (16) 
30 (31) 
0.081 
Nuclear MCT-2 
Low 
High 
 
75 (75) 
24 (69) 
 
25 (25) 
11 (31) 
0.464 
Cytoplasmic LDH-1 
Low 
High 
 
18 (69) 
81 (74) 
 
8 (31) 
28 (26) 
0.603 
Nuclear LDH-1 
Low 
High 
 
35 (76) 
64 (72) 
 
11 (24) 
25 (28) 
0.601 
Cytoplasmic LDH-5 
Low 
High 
 
32 (65) 
67 (78) 
 
17 (35) 
19 (22) 
0.115 
Nuclear LDH-5 
Low 
High 
 
41 (67) 
58 (78) 
 
20 (33) 
16 (22) 
0.125 
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Table 3. Relationship between metabolic markers and clinicopathological 
characteristics in patients undergoing potentially curative resection of colorectal cancer 
(n=150). 
  
  Nuclear LDH5 Cytoplasmic MCT-2 + TSP Nuclear LDH-5 + TSP 
Low 
(n=67) High (n=83) P 
Both Low/One 
High 
(n=105) Both High (n=30) P 
Both Low/One 
High 
(n=119) Both High (n=16) P 
Age 
<65 
>65 
 
27 (40) 
40 (60) 
 
31 (37) 
52 (63) 
0.682  
37 (35) 
68 (65) 
 
15 (50) 
15 (50) 
0.152  
46 (39) 
73 (61) 
 
6 (37) 
10 (63) 
0.705 
Sex 
Female 
Male 
 
34 (51) 
33 (49) 
 
34 (41) 
49 (59) 
0.231  
52 (49) 
53 (51) 
 
12 (40) 
18 (60) 
0.359  
59 (50) 
60 (50) 
 
5 (31) 
11 (69) 
0.162 
Adjuvant 
No 
Yes 
 
49 (73) 
18 (27) 
 
62 (75) 
21 (25) 
0.828  
83 (79) 
22 (21) 
 
18 (60) 
12 (40) 
0.040  
90 (76) 
29 (24) 
 
11 (69) 
5 (31) 
0.560 
Tumour site 
Colon (right-side) 
Colon (left-side) 
Rectum 
 
22 (33) 
26 (39) 
19 (28) 
 
31 (37) 
20 (24) 
32 (39) 
0.138  
36 (34) 
30 (29) 
39 (37) 
 
11 (37) 
11 (37) 
8 (26) 
0.458  
43 (36) 
35 (29) 
41 (35) 
 
4 (26) 
6 (37) 
6 (37) 
0.525 
TNM-stage 
I 
II 
III 
 
9 (13) 
30 (45) 
28 (42) 
 
5 (6) 
42 (51) 
36 (43) 
0.292  
12 (11) 
54 (52) 
39 (37) 
 
2 (7) 
12 (40) 
16 (53) 
0.119  
13 (11) 
58 (49) 
48 (40) 
 
1 (6) 
8 (50) 
7 (44) 
0.640 
Differentiation 
Mod/well 
Poor 
 
60 (90) 
7 (10) 
 
72 (87) 
11 (13) 
0.597  
92 (88) 
13 (12) 
 
27 (90) 
3 (10) 
0.723  
105 (88) 
14 (12) 
 
14 (88) 
2 (12) 
0.932 
Venous invasion 
Absent 
Present 
 
44 (66) 
23 (34) 
 
52 (63) 
31 (37) 
0.701  
69 (66) 
36 (34) 
 
17 (57) 
13 (43) 
0.367  
78 (66) 
41 (34) 
 
8 (50) 
8 (50) 
0.233 
Margin involvement 
No 
Yes 
 
62 (93) 
5 (7) 
 
78 (94) 
5 (6) 
0.726  
98 (93) 
7 (7) 
 
28 (93) 
2 (7) 
1.000  
112 (94) 
7 (6) 
 
14 (88) 
2 (12) 
0.362 
Peritoneal involvement 
No 
Yes 
 
54 (81) 
13 (19) 
 
57 (69) 
26 (31) 
0.095  
79 (75) 
26 (25) 
 
22 (73) 
8 (27) 
0.833  
92 (77) 
27 (23) 
 
9 (56) 
7 (44) 
0.083 
Necrosis  
Low 
High 
 
41 (62) 
25 (38) 
 
45 (55) 
37 (45) 
0.374  
58 (56) 
45 (44) 
 
23 (77) 
7 (23) 
0.039  
68 (58) 
49 (42) 
 
13 (81) 
3 (19) 
0.063 
Tumour budding 
Low 
High 
 
40 (71) 
16 (29) 
 
53 (65) 
29 (35) 
0.401  
73 (72) 
28 (28) 
 
12 (43) 
16 (57) 
0.004  
80 (71) 
33 (29) 
 
5 (31) 
11 (69) 
0.002 
Mismatch repair status  
Competent 
Deficient 
 
53 (88) 
7 (12) 
 
64 (81) 
15 (19) 
0.236  
81 (84) 
16 (16) 
 
26 (90) 
3 (10) 
0.400  
93 (84) 
18 (16) 
 
15 (93) 
1 (7) 
0.289 
Proliferation Index 
Low 
High 
 
24 (38) 
40 (62) 
 
40 (50) 
40 (50) 
0.133  
74 (73) 
28 (27) 
 
24 (86) 
4 (14) 
0.134  
86 (75) 
29 (25) 
 
12 (80) 
3 (20) 
0.653 
Klintrup-Makinen grade 
Strong 
Weak 
 
20 (30) 
47 (70) 
 
27 (33) 
56 (67) 
0.725  
34 (32) 
71 (68) 
 
10 (33) 
20 (67) 
0.922  
39 (33) 
80 (67) 
 
5 (31) 
11 (69) 
0.903 
mGPS 
0 
1 
2 
 
42 (63) 
18 (27) 
7 (10) 
 
41 (49) 
31 (37) 
11 (14) 
0.161  
61 (58) 
33 (31) 
11 (11) 
 
17 (57) 
10 (33) 
3 (10) 
0.946  
70 (59) 
36 (30) 
13 (11) 
 
8 (50) 
7 (44) 
1 (6) 
0.818 
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Table 4. Relationship between metabolic markers and inflammatory response in 
patients undergoing potentially curative resection of colorectal cancer (n=150). 
 
  Nuclear LDH5 Cytoplasmic MCT-2 + TSP Nuclear LDH-5 + TSP 
Low 
(n=67) High (n=83) P 
Both Low/One 
High 
(n=105) Both High (n=30) P 
Both Low/One 
High 
(n=119) Both High (n=16) P 
CD3+ lymphocytes - Margin 
Low 
High 
 
35 (56) 
44 (28) 
 
45 (60) 
30 (40) 
0.598  
59 (62) 
37 (38) 
 
13 (45) 
16 (55) 
0.114  
63 (57) 
47 (43) 
 
9 (60) 
6 (40) 
0.841 
CD3+ lymphocytes - Stroma 
Low 
High 
 
29 (45) 
36 (55) 
 
41 (51) 
39 (49) 
0.426  
47 (47) 
54 (53) 
 
14 (47) 
16 (53) 
0.990  
49 (43) 
66 (57) 
 
12 (75) 
4 (25) 
0.014 
CD3+ lymphocytes - Centre 
Low 
High 
 
44 (68) 
21 (32) 
 
53 (66) 
27 (34) 
0.854  
68 (67) 
33 (33) 
 
22 (73) 
8 (27) 
0.529  
78 (68) 
37 (32) 
 
12 (75) 
4 (25) 
0.555 
Cytotoxic T-cells - Margin 
Low 
High 
 
39 (63) 
23 (37) 
 
45 (61) 
29 (39) 
0.802  
59 (61) 
37 (39) 
 
15 (54) 
13 (46) 
0.481  
63 (58) 
45 (42) 
 
10 (67) 
5 (33) 
0.534 
Cytotoxic T-cells - Stroma 
Low 
High 
 
45 (74) 
16 (26) 
 
56 (70) 
24 (30) 
0.622  
71 (71) 
29 (29) 
 
20 (69) 
9 (31) 
0.833  
81 (72) 
32 (28) 
 
10 (63) 
6 (37) 
0.460 
Cytotoxic T-cells - Centre 
Low 
High 
 
47 (76) 
15 (24) 
 
53 (66) 
27 (33) 
0.213  
70 (70) 
30 (30) 
 
21 (72) 
8 (28) 
0.801  
81 (72) 
32 (28) 
 
10 (63) 
6 (37) 
0.460 
Memory T-cells - Margin 
Low 
High 
 
35 (57) 
27 (43) 
 
44 (58) 
32 (42) 
0.865  
56 (57) 
42 (43) 
 
15 (54) 
13 (46) 
0.737  
62 (56) 
49 (44) 
 
9 (60) 
6 (40) 
0.761 
Memory T-cells - Stroma 
Low 
High 
 
29 (45) 
36 (55) 
 
38 (48) 
42 (52) 
0.729  
46 (45) 
57 (55) 
 
11 (39) 
17 (61) 
0.610  
48 (41) 
68 (59) 
 
9 (60) 
6 (40) 
0.173 
Memory T-cells - Centre 
Low 
High 
 
49 (75) 
16 (25) 
 
58 (73) 
22 (27) 
0.694  
75 (73) 
28 (27) 
 
22 (78) 
6 (22) 
0.532  
86 (74) 
30 (25) 
 
11 (73) 
4 (27) 
0.947 
Tregs - Margin 
Low 
High 
 
30 (49) 
31 (51) 
 
50 (67) 
25 (33) 
0.039  
55 (57) 
41 (43) 
 
18 (67) 
9 (33) 
0.377  
62 (56) 
47 (43) 
 
11 (79) 
3 (21) 
0.107 
Tregs - Stroma 
Low 
High 
 
31 (50) 
31 (50) 
 
58 (73) 
21 (27) 
0.004  
59 (60) 
40 (40) 
 
19 (68) 
9 (32) 
0.424  
66 (59) 
46 (41) 
 
12 (80) 
3 (20) 
0.101 
Tregs - Centre 
Low 
High 
 
25 (40) 
37 (60) 
 
48 (62) 
30 (38) 
0.012  
48 (49) 
50 (51) 
 
15 (54) 
13 (46) 
0.668  
53 (48) 
58 (52) 
 
10 (67) 
5 (33) 
0.165 
Serum CRP 
Normal 
High 
 
42 (63) 
25 (37) 
 
41 (49) 
42 (51) 
0.103  
61 (58) 
44 (42) 
 
17 (57) 
13 (43) 
0.889  
70 (59) 
49 (41) 
 
8 (50) 
8 (50) 
0.505 
Serum Albumin 
Normal  
Low 
 
56 (84) 
11 (16) 
 
71 (86) 
12 (14) 
0.741  
91 (87) 
14 (13) 
 
25 (83) 
5 (17) 
0.649  
102 (86) 
17 (14) 
 
14 (88) 
2 (12) 
0.845 
Serum Neutrophils 
Low 
High 
 
50 (86) 
8 (14) 
 
55 (81) 
13 (19) 
0.422  
73 (83) 
15 (17) 
 
19 (76) 
6 (24) 
0.441  
82 (82) 
18 (18) 
 
10 (77) 
3 (23) 
0.666 
Serum Lymphocytes 
Low 
High 
 
45 (78) 
13 (12) 
 
51 (75) 
17 (25) 
0.734  
63 (72) 
25 (28) 
 
21 (84) 
4 (16) 
0.193  
72 (72) 
28 (28) 
 
12 (92) 
1 (8) 
0.080 
White Cell Count 
Low 
Intermediate 
High 
 
36 (62) 
16 (28) 
6 (10) 
 
44 (60) 
16 (22) 
13 (17) 
0.423  
53 (58) 
26 (28) 
13 (14) 
 
17 (68) 
3 (12) 
5 (20) 
0.789  
60 (58) 
29 (28) 
15 (14) 
 
10 (77) 
0 (0) 
3 (23) 
0.631 
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Table 5.   Clinicopathological characteristics of patients undergoing potentially curative 
resection of colorectal cancer and cancer-specific survival (n=150) 
 
Univariate HR 
(95% CI) P 
Multivariate HR 
(95% CI) P 
Clinicopathological Characteristics     
Age (<65/>65) 1.14 (0.84-1.53) 0.403 - - 
Sex (Female/Male) 1.21 (0.72-2.01) 0.471 - - 
Adjuvant Therapy (No/Yes) 0.89 (0.50-1.60) 0.707 - - 
Tumour Site (Colon (right)/colon (left)/Rectum) 1.22 (0.90-1.65) 0.203 - - 
TNM-Stage (II/III) 2.03 (1.31-3.13) 0.002 1.36 (0.79-2.35) 0.268 
Differentiation (Moderate or well/Poor) 1.41 (0.67-2.96) 0.366 - - 
Venous Invasion (Absent/Present) 1.93 (1.17-3.18) 0.011 1.74 (0.99-3.06) 0.053 
Margin Involvement (No/Yes) 2.45 (1.05-5.72) 0.038 2.57 (0.97-6.81) 0.058 
Peritoneal Involvement (No/Yes) 1.60 (0.94-2.72) 0.085 - - 
Necrosis (Low/High) 1.31 (0.79-2.17) 0.304 - - 
Mismatch Repair Status (Competent/Deficient) 1.06 (0.52-2.16) 0.879 - - 
Ki67 proliferation Index (Low/High) 0.52 (0.31-0.86) 0.012 0.91 (0.46-1.80) 0.791 
Tumour budding (yes/no) 3.87 (2.27-6.60) <0.001 3.19 (1.84-5.56) <0.001 
Inflammatory Characteristics     
Klintrup-Makinen Grade (Strong/Weak) 2.15 (1.14-4.04) 0.018 1.84 (0.95-3.59) 0.072 
mGPS (0/1/2) 2.03 (1.45-2.82) <0.001 2.21 (1.50-3.26) <0.001 
Metabolism markers     
Nuclear LDH-5 1.68 (0.99-2.84) 0.050 1.19 (0.62-2.29) 0.606 
Cytoplasmic LDH-5 1.76 (0.97-3.20) 0.058 1.85 (0.97-3.53) 0.063 
Cytoplasmic MCT-2+TSP 2.32 (1.31-4.11) 0.003 1.38 (0.71-2.71) 0.344 
Nuclear LDH-5+TSP 3.70 (1.96-6.98) <0.001 2.61 (1.27-5.35) 0.009 
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Figure 1. Metabolic markers are associated with poor prognosis in patients with 
colorectal cancer (n=150). Kaplan Meier curves showing associations between CSS and (A) 
Nuclear LDH-5, (B) cytoplasmic LDH-5, (C) cytoplasmic MCT-2+TSP and (D) nuclear 
LDH-5+TSP in 150 patients with stage I-III CRC. 
 
 
